MA57599B1 - Semaglutide pour le traitement de la démence d'alzheimer - Google Patents

Semaglutide pour le traitement de la démence d'alzheimer

Info

Publication number
MA57599B1
MA57599B1 MA57599A MA57599A MA57599B1 MA 57599 B1 MA57599 B1 MA 57599B1 MA 57599 A MA57599 A MA 57599A MA 57599 A MA57599 A MA 57599A MA 57599 B1 MA57599 B1 MA 57599B1
Authority
MA
Morocco
Prior art keywords
semaglutide
dementia
alzheimer
treatment
glp
Prior art date
Application number
MA57599A
Other languages
English (en)
Inventor
Anna SECHER
Sarah FRIEDRICH
Charlotte Christine Thim HANSEN
Lotte Bjerre Knudsen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73172681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA57599(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of MA57599B1 publication Critical patent/MA57599B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des thérapies médicales améliorées pour toutes les formes et stades de la démence impliquant l'administration (i) d'agonistes du récepteur de GLP-1 à des sujets présentant un syndrome métabolique ou (ii) de sémaglutide.
MA57599A 2019-11-06 2020-11-05 Semaglutide pour le traitement de la démence d'alzheimer MA57599B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19207501 2019-11-06
EP20186623 2020-07-20
PCT/EP2020/081087 WO2021089678A1 (fr) 2019-11-06 2020-11-05 Agonistes du récepteur glp-1 dans la démence
EP20803489.2A EP4054620B1 (fr) 2019-11-06 2020-11-05 Semaglutide pour le traitement de la démence d'alzheimer

Publications (1)

Publication Number Publication Date
MA57599B1 true MA57599B1 (fr) 2024-06-28

Family

ID=73172681

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57599A MA57599B1 (fr) 2019-11-06 2020-11-05 Semaglutide pour le traitement de la démence d'alzheimer

Country Status (19)

Country Link
US (4) US20220280612A1 (fr)
EP (2) EP4414031A3 (fr)
JP (2) JP7670698B2 (fr)
KR (1) KR20220110731A (fr)
CN (1) CN114728042A (fr)
AU (1) AU2020377469A1 (fr)
BR (1) BR112022007721A2 (fr)
CA (1) CA3154744A1 (fr)
ES (1) ES2984177T3 (fr)
HR (1) HRP20241052T1 (fr)
HU (1) HUE067514T2 (fr)
IL (1) IL291876A (fr)
MA (1) MA57599B1 (fr)
MX (1) MX2022004779A (fr)
PH (1) PH12022550842A1 (fr)
PL (1) PL4054620T3 (fr)
RS (1) RS65780B1 (fr)
TW (1) TWI890704B (fr)
WO (1) WO2021089678A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291876A (en) 2019-11-06 2022-06-01 Novo Nordisk As Receptor agonists in glp-1 type dementia
KR20220132606A (ko) * 2020-01-30 2022-09-30 일라이 릴리 앤드 캄파니 둘라글루티드의 치료 용도
US20240050531A1 (en) * 2020-12-16 2024-02-15 The Chinese University Of Hong Kong A method for reversing aging brain functional decline
KR20240123816A (ko) 2021-12-02 2024-08-14 쾨벤하운스 유니버시테트 퇴행성 신경 질환의 치료를 위한 펩티드-약물 접합체
WO2024179606A1 (fr) * 2023-03-02 2024-09-06 甘李药业股份有限公司 Utilisation médicale d'un composé de glp-1
CN120131965A (zh) * 2025-04-10 2025-06-13 瓯江实验室 Glp-1受体激动剂治疗阿尔茨海默病的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
WO2001092206A1 (fr) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Procede de preparation de salicylamides
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN101258163B (zh) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
WO2007121318A2 (fr) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Préparations destinées à l'administration d'insuline
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
SI2651398T1 (en) * 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
WO2013004983A1 (fr) 2011-07-04 2013-01-10 Imperial Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
EP2866825B1 (fr) * 2012-07-01 2020-04-08 Novo Nordisk A/S Utilisation de peptides glp-1 à action prolongée
ES2741507T3 (es) 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
WO2016198624A1 (fr) * 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
CN108697768B (zh) 2015-12-23 2022-07-22 约翰霍普金斯大学 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
US20190142905A1 (en) 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
IL291876A (en) 2019-11-06 2022-06-01 Novo Nordisk As Receptor agonists in glp-1 type dementia
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Also Published As

Publication number Publication date
US20230302094A1 (en) 2023-09-28
HRP20241052T1 (hr) 2024-11-08
EP4054620A1 (fr) 2022-09-14
EP4414031A3 (fr) 2025-02-05
EP4054620C0 (fr) 2024-05-29
CA3154744A1 (fr) 2021-05-14
HUE067514T2 (hu) 2024-10-28
EP4414031A2 (fr) 2024-08-14
JP2023500032A (ja) 2023-01-04
RS65780B1 (sr) 2024-08-30
WO2021089678A1 (fr) 2021-05-14
CN114728042A (zh) 2022-07-08
TW202519256A (zh) 2025-05-16
US12539326B2 (en) 2026-02-03
KR20220110731A (ko) 2022-08-09
ES2984177T3 (es) 2024-10-29
US20220280612A1 (en) 2022-09-08
TW202118509A (zh) 2021-05-16
AU2020377469A1 (en) 2022-04-28
MX2022004779A (es) 2022-06-14
JP7670698B2 (ja) 2025-04-30
EP4054620B1 (fr) 2024-05-29
JP2025027130A (ja) 2025-02-26
IL291876A (en) 2022-06-01
TWI890704B (zh) 2025-07-21
US20250099549A1 (en) 2025-03-27
US20240207364A1 (en) 2024-06-27
PL4054620T3 (pl) 2024-10-14
PH12022550842A1 (en) 2023-10-09
BR112022007721A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
MA57599B1 (fr) Semaglutide pour le traitement de la démence d'alzheimer
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
Spudich Immune activation in the central nervous system throughout the course of HIV infection
Boada et al. Neuropsychological, neuropsychiatric, and quality‐of‐life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study
Shah et al. Acquired neurosyphilis presenting as movement disorders
MA40224A (fr) Anticorps se liant aux protofibrilles ass améliorés
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MA45543B1 (fr) Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations
MX2021010696A (es) Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
EA202190569A1 (ru) Способы лечения болезни фабри у пациентов, имеющих мутацию в гене gla
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
MX2019006141A (es) Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.
EP3960858A4 (fr) Petit médicament à base d'arn pour la prévention et le traitement de maladies liées à une l'inflammation et leur combinaison
EA202190755A1 (ru) Агенты для терапии и диагностики рака
MA32299B1 (fr) Utilisation de la dronedarone pour preparer un medicament pour le traitement de patients ayant une arythmie et ayant une augmentation du taux de creatinine due a l'administration de dronedarone
MA56998B1 (fr) Traitement de symptômes induits par le cycle menstruel
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
EP3443984A4 (fr) Composition pharmaceutique pour diminuer les symptômes et la maladie de l'infection respiratoire causée par le métapneumovirus humain (hmpv) qui comprend au moins un agent neutralisant la fonction des molécules tspl et/ou tslpr, et/ou ox40l et/ou cd177, et un excipient pharmaceutiquement acceptable, et leur utilisation
Huang et al. Rosiglitazone suppresses HIV-1 Tat-induced vascular inflammation via Akt signaling
MA33455B1 (fr) Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
FR3073398B1 (fr) Triterpenes pentacycliques dans le traitement d'une pathologie bucco-dentaire
Chirumbolo et al. Post‑COVID or long‑COVID? That is the question
CA3156182A1 (fr) Procedes de traitement d'etats lies au recepteur s1p1